明德生物(002932.SZ):公司研製的新型冠狀病毒核酸檢測試劑盒投入臨牀使用需要一定週期
格隆匯2月3日丨明德生物(002932.SZ)公佈,公司股票交易價格連續2個交易日(2020年1月23日、2020年2月3日)累計漲幅達16.19%。
公司關注到近日相關媒體和投資者對公司目前已研製出新型冠狀病毒(2019-nCoV)核酸檢測試劑盒(多重熒光PCR法)給予了關注,現對相關情況進行説明並風險提示如下:
該檢測試劑盒尚需經國家藥品監督管理局的驗證、考核和批准註冊,投入臨牀使用需要一定的週期,在時間上存在不確定因素,所以在臨牀領域的規模性上市和廣泛應用存在很大的不確定性。
目前國內外多家科研機構和廠家已經在研製或研製成功同類的檢測產品,所以公司的產品不是唯一的。
鑑於上述檢測試劑產品註冊時間的不確定性、產品的非唯一性和市場需求的變化以及同類產品競爭等因素的影響,上述檢測試劑盒的成功研製對公司短期業績產生實質性的影響有限,對未來業績是否帶來有利影響還存在重大的不確定性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.